Skip to main content
profile image
Selected Works of Christopher Forest
Article
The role of SGLT2 inhibitors in managing Type 2 Diabetes
JAAPA (2018)
  • Velen Tat
  • Christopher Forest, California State University, Monterey Bay
Link Find in your library
Abstract
The sodium glucose cotransporter 2 (SGLT2) inhibitors canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin represent a novel class of medications to manage type 2 diabetes through urinary excretion of glucose. These drugs block glucose reabsorption by the kidneys to increase glucosuria. These drugs provide hemoglobin A1C reduction, promote weight loss, and remain hypoglycemic-neutral when not used in combination with insulin or secretagogues. Canagliflozin and empagliflozin have shown cardiovascular benefit. The potential to reduce the risk of cardiovascular death in patients with type 2 diabetes, along with the benefit of weight reduction, makes these new agents useful tools for the primary care provider.
Keywords
  • Diabetes,
  • SGLT2 Inhibitors,
  • Type 2 Diabetes
Disciplines
Publication Date
June, 2018
DOI
10.1097/01.JAA.0000533660.86287.04
Citation Information
Velen Tat and Christopher Forest. "The role of SGLT2 inhibitors in managing Type 2 Diabetes" JAAPA Vol. 31 Iss. 6 (2018) p. 35 - 40
Available at: http://works.bepress.com/christopher-forest/32/